7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration

Key Takeaways Explain This Topic AI

Norepinephrine is the first-line vasopressor for septic, distributive, and cardiogenic shock due to potent α 1 \alpha_1 α 1 ​ vasoconstriction and modest β 1 \beta_1 β 1 ​ inotropy, providing reliable MAP elevation with substantially lower arrhythmogenicity than dopamine.

Vasopressin acts as a pure non-adrenergic vasoconstrictor via vascular smooth muscle V 1 V_1 V 1 ​ receptors; administered at a fixed, non-titrated dose of 0.03 units/min, it restores vasomotor tone in relative vasopressin deficiency and significantly reduces catecholamine requirements.

Epinephrine provides potent combined α 1 \alpha_1 α 1 ​ and β 1 / β 2 \beta_1/\beta_2 β 1 ​ / β 2 ​ adrenergic stimulation, serving as first-line therapy in cardiac arrest and anaphylaxis and second-line in refractory septic shock; it characteristically induces benign, self-limited Type B hyperlactatemia via skeletal muscle β 2 \beta_2 β 2 ​ -stimulated aerobic glycolysis.

Dobutamine (predominantly β 1 > β 2 \beta_1 > \beta_2 β 1 ​ > β 2 ​ ) enhances myocardial contractility and cardiac output with mild systemic vasodilation, whereas milrinone (a PDE-3 inhibitor) increases intracellular cAMP independently of adrenergic receptors, making it preferred in pulmonary hypertension with RV failure and in patients on chronic beta-blockers, though it accumulates in acute kidney injury.

Dopamine produces dose-dependent receptor stimulation ( D 1 D_1 D 1 ​ at low doses, β 1 \beta_1 β 1 ​ at moderate, α 1 \alpha_1 α 1 ​ at high doses); the randomized SOAP II trial showed more tachyarrhythmias with dopamine than norepinephrine and, in the cardiogenic shock subgroup, higher 28-day mortality, while low-dose 'renal' dopamine confers no nephroprotection.

Last updated: October 2026

Vasoactive infusions represent the primary pharmacologic arm of hemodynamic resuscitation in the intensive care unit. When fluid administration fails to restore adequate end-organ perfusion, vasopressors and inotropes are deployed to maintain mean arterial pressure ( MAP \text{MAP} MAP ), improve cardiac output, and preserve microvascular blood flow. Selecting and titrating these agents requires a sophisticated grasp of receptor affinity, intracellular secondary messenger cascades, systemic and regional vascular responses, and the adverse metabolic signatures unique to each drug class.

1. Receptor Pharmacology & Intracellular Signaling Cascades

Vasoactive agents actuate five primary transmembrane receptor families located on vascular smooth muscle, cardiac myocytes, and specialized conduction tissues: Vasoactive Receptor Signaling Pathways:

[ α1 Receptor ] ──> Gq Protein ──> Phospholipase C (PLC) ──> IP3 + DAG ──> Intracellular Ca2+ Release ──> Vasoconstriction

[ β1 Receptor ] ──> Gs Protein ──> Adenylyl Cyclase ──> cAMP ──> PKA ──> L-type Ca2+ / Phospholamban ──> Inotropy / Chronotropy

[ β2 Receptor ] ──> Gs Protein ──> Adenylyl Cyclase ──> cAMP ──> PKA ──> MLCK Inactivation / Ca2+ Efflux ──> Vasodilation / Glycolysis

[ V1 Receptor ] ──> Gq Protein ──> Phospholipase C (PLC) ──> IP3 + DAG ──> Sarcoplasmic Ca2+ Release ──> Non-Adrenergic Vasoconstriction

[ D1 Receptor ] ──> Gs Protein ──> Adenylyl Cyclase ──> cAMP ──> Smooth Muscle Relaxation ──> Renal / Mesenteric Vasodilation

Alpha-1 ( α 1 \alpha_1 α 1 ​ ) Adrenergic Receptors

Distribution: Postsynaptic vascular smooth muscle throughout arterial and venous resistance beds.

Coupling & Mechanism: Coupled to the G q G_q G q ​ heterotrimeric protein. Activation stimulates phospholipase C (PLC), cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses to the sarcoplasmic reticulum, binding specific IP3 receptors to trigger rapid calcium efflux into the cytosol. Calcium binds calmodulin, activating myosin light-chain kinase (MLCK), which phosphorylates myosin regulatory light chains, driving cross-bridge cycling, vascular smooth muscle contraction, and systemic vasoconstriction.

Hemodynamic Effect: Substantial elevation in systemic vascular resistance (SVR), elevation of mean arterial pressure (MAP), and venous capacitance vessel constriction, which increases mean systemic filling pressure ( P msf P_{\text{msf}} P msf ​ ) and mobilizes unstressed vascular volume into stressed volume to augment venous return.

Beta-1 ( β 1 \beta_1 β 1 ​ ) Adrenergic Receptors

Distribution: Sinoatrial (SA) node, atrioventricular (AV) node, and ventricular myocardium.

Coupling & Mechanism: Coupled to the stimulatory G s G_s G s ​ protein. Agonism activates membrane-bound adenylyl cyclase, converting adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). cAMP activates protein kinase A (PKA), which phosphorylates three critical targets:

L-type voltage-gated calcium channels on the sarcolemma, increasing inward calcium trigger current.

Ryanodine receptors (RyR2) on the sarcoplasmic reticulum, amplifying calcium-induced calcium release.

Phospholamban , relieving its tonic inhibition of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a), which accelerates cytosolic calcium reuptake into the sarcoplasmic reticulum.

Hemodynamic Effect: Positive inotropy (enhanced peak systolic force), positive chronotropy (increased heart rate via pacemaker I f I_f I f ​ current acceleration), positive dromotropy (hastened AV conduction), and positive lusitropy (accelerated myocardial relaxation during diastole).

Beta-2 ( β 2 \beta_2 β 2 ​ ) Adrenergic Receptors

Distribution: Vascular smooth muscle of skeletal muscle and splanchnic circulation, bronchial smooth muscle, hepatocytes, and skeletal myocytes.

Coupling & Mechanism: Coupled via G s G_s G s ​ to adenylyl cyclase and cAMP. Unlike in cardiac tissue, elevated cAMP in vascular smooth muscle phosphorylates MLCK, inhibiting its affinity for the calcium-calmodulin complex, while simultaneously stimulating calcium extrusion and sequestration.

Hemodynamic & Metabolic Effect: Systemic vasodilation (reducing SVR) and bronchodilation. In skeletal muscle and hepatocytes, β 2 \beta_2 β 2 ​ agonism stimulates glycogen phosphorylase and cyclic AMP-dependent glycogenolysis and glycolysis, directly accelerating pyruvate and lactate generation.

Vasopressin-1 ( V 1 \text{V}_1 V 1 ​ ) Receptors

Distribution: Vascular smooth muscle of systemic arterial resistance vessels.

Coupling & Mechanism: Coupled via G q G_q G q ​ to the PLC/ IP 3 \text{IP}_3 IP 3 ​ /DAG pathway, driving intracellular calcium release and smooth muscle contraction. Crucially, V 1 V_1 V 1 ​ receptor signaling remains functionally intact during profound metabolic and respiratory acidosis, circumstances under which adrenergic receptors undergo conformational desensitization and intracellular uncoupling.

Dopamine-1 ( D 1 \text{D}_1 D 1 ​ ) Receptors

Distribution: Renal, mesenteric, coronary, and cerebral arterial vascular beds.

Coupling & Mechanism: Coupled via G s G_s G s ​ to adenylyl cyclase, promoting vascular smooth muscle relaxation and selective regional vasodilation at low infusion concentrations.

• 2. Catecholamine Vasopressors: Clinical Pharmacology & Evidence
• Norepinephrine: The Foundational First-Line Vasopressor

Norepinephrine is the first-line vasopressor for septic, distributive, and cardiogenic shock across international guidelines, including the Surviving Sepsis Campaign (SSC).

Receptor Selectivity: Potent α 1 \alpha_1 α 1 ​ agonist with moderate β 1 \beta_1 β 1 ​ activity ( α 1 ≫ β 1 > β 2 \alpha_1 \gg \beta_1 > \beta_2 α 1 ​ ≫ β 1 ​ > β 2 ​ ).

Hemodynamics: Produces robust peripheral vasoconstriction that increases SVR, diastolic blood pressure, and MAP. Because of its concurrent β 1 \beta_1 β 1 ​ activity, stroke volume and contractility are maintained or augmented, preventing the drop in cardiac output frequently seen with pure α 1 \alpha_1 α 1 ​ agonists. Its net effect on heart rate is neutral to mildly positive; the direct β 1 \beta_1 β 1 ​ chronotropic stimulus is counterbalanced by baroreceptor-mediated vagal deceleration as aortic root pressure rises.

Dosing & Titration: Standard continuous infusion starts at 0.01 – 0.05 μ g/kg/min 0.01\text{--}0.05\,\mu\text{g/kg/min} 0.01 – 0.05 μ g/kg/min (or 2 – 5 μ g/min 2\text{--}5\,\mu\text{g/min} 2 – 5 μ g/min in fixed-dose units) and is titrated rapidly every 2 to 5 minutes to achieve a target MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg . Requirements above about 1 μ g/kg/min 1\,\mu\text{g/kg/min} 1 μ g/kg/min define refractory shock; vasopressin is commonly added at about 0.25 – 0.5 μ g/kg/min 0.25\text{--}0.5\,\mu\text{g/kg/min} 0.25 – 0.5 μ g/kg/min , and secondary non-adrenergic adjuncts should be initiated early.

Clinical Superiority: Compared to dopamine, norepinephrine produces equivalent or superior MAP elevation with significantly fewer tachydysrhythmias (atrial fibrillation, ventricular tachycardia) and lower 28-day mortality in cardiogenic shock.

Vasopressin: The Non-Adrenergic Catecholamine-Sparing Adjunct

Arginine vasopressin (AVP) is an endogenous nonapeptide hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and stored in the posterior pituitary (neurohypophysis).

Pathophysiology of Relative Deficiency: In the initial compensatory phase of shock, neurohypophyseal stores release massive bursts of vasopressin. However, within 24 to 48 hours of sustained distributive shock, pituitary stores become exhausted, leading to an absolute or relative vasopressin deficiency characterized by inappropriately low circulating plasma levels despite profound hypotension.

Dosing & Titration Rule: In distributive shock, vasopressin is administered at a fixed, non-titrated dose of 0.03 units/min 0.03\text{ units/min} 0.03 units/min (or 0.01 – 0.03 units/min 0.01\text{--}0.03\text{ units/min} 0.01 – 0.03 units/min ). It should not be titrated up and down like catecholamines. Titrating doses above 0.04 units/min 0.04\text{ units/min} 0.04 units/min adds little pressor benefit and causes intense V 1 V_1 V 1 ​ -mediated vasoconstriction of the coronary, splanchnic, and cutaneous microcirculation, culminating in intestinal ischemia, acute mesenteric infarction, and distal digital necrosis.

Trial Evidence:

VASST Trial (Russell et al., NEJM 2008): Randomized 778 septic shock patients to low-dose vasopressin ( 0.03 units/min 0.03\text{ units/min} 0.03 units/min ) versus open-label norepinephrine. While 28-day overall mortality did not differ significantly (35.4% vs 39.3%, p = 0.26 p = 0.26 p = 0.26 ), a predefined subgroup analysis of milder septic shock (baseline norepinephrine < 15 μ g/min < 15\,\mu\text{g/min} < 15 μ g/min ) showed lower mortality with vasopressin (26.5% vs 35.7%, p = 0.05 p = 0.05 p = 0.05 ).

VANISH Trial (Gordon et al., JAMA 2016): Evaluated early vasopressin versus norepinephrine in septic shock, confirming catecholamine-sparing; the primary outcome (kidney failure-free days) did not differ, although RRT use was lower with vasopressin as a secondary finding.

Epinephrine: Potent Agonism with Metabolic Trade-offs

Epinephrine is an endogenous catecholamine exhibiting balanced, high-affinity agonism across α 1 \alpha_1 α 1 ​ , β 1 \beta_1 β 1 ​ , and β 2 \beta_2 β 2 ​ adrenergic receptors.

Receptor Selectivity: Non-selective agonist ( β 1 = β 2 > α 1 \beta_1 = \beta_2 > \alpha_1 β 1 ​ = β 2 ​ > α 1 ​ at low doses; α 1 \alpha_1 α 1 ​ predominates at higher infusion rates > 0.1 μ g/kg/min > 0.1\,\mu\text{g/kg/min} > 0.1 μ g/kg/min ).

Indications:

First-line drug of choice for anaphylactic shock (intramuscular 0.3 – 0.5 mg 0.3\text{--}0.5\text{ mg} 0.3 – 0.5 mg into the anterolateral thigh) and cardiac arrest (1 mg IV push every 3 to 5 minutes).

Second- or third-line adjunct in refractory septic shock when MAP remains inadequate despite dual norepinephrine and vasopressin infusions, or when severe septic cardiomyopathy accompanies distributive vasoplegia.

Post-cardiotomy cardiogenic shock and failure to wean from cardiopulmonary bypass.

The Epinephrine Hyperlactatemia Phenomenon: A common, predictable occurrence after epinephrine initiation is an acute increase in serum lactate within the first hours of infusion. This is Type B hyperlactatemia (aerobic glycolysis), not indicative of worsening tissue hypoperfusion, anaerobic metabolism, or therapeutic failure:

Epinephrine → β 2 Receptors ↑ cAMP → Accelerated Glycogenolysis → Pyruvate Exceeds PDH Capacity → Lactate Conversion \text{Epinephrine} \xrightarrow{\beta_2\text{ Receptors}} \uparrow \text{cAMP} \xrightarrow{} \text{Accelerated Glycogenolysis} \xrightarrow{} \text{Pyruvate Exceeds PDH Capacity} \xrightarrow{} \text{Lactate Conversion} Epinephrine β 2 ​ Receptors ​ ↑ cAMP ​ Accelerated Glycogenolysis ​ Pyruvate Exceeds PDH Capacity ​ Lactate Conversion

Note

When evaluating an epinephrine-treated patient with rising lactate, clinicians must assess clinical markers of systemic perfusion: central venous oxygen saturation ( ScvO 2 > 70 % \text{ScvO}_2 > 70\% ScvO 2 ​ > 70% ), urine output ( > 0.5 mL/kg/hr > 0.5\text{ mL/kg/hr} > 0.5 mL/kg/hr ), capillary refill time ( < 3 s < 3\text{ s} < 3 s ), and base deficit. If clinical perfusion is restored, rising lactate represents benign β 2 \beta_2 β 2 ​ -driven aerobic glycolysis and does not warrant vasopressor escalation.

Phenylephrine: Pure Alpha-1 Vasoconstriction

Phenylephrine is a synthetic noncatecholamine with exclusive, direct α 1 \alpha_1 α 1 ​ -adrenergic receptor agonism, completely lacking β 1 \beta_1 β 1 ​ or β 2 \beta_2 β 2 ​ activity.

Hemodynamics: Markedly elevates SVR and arterial blood pressure. The abrupt surge in systemic afterload activates carotid sinus and aortic arch baroreceptors, producing potent vagal efferent discharge that triggers reflex bradycardia .

Impact on Cardiac Output: Because it lacks β 1 \beta_1 β 1 ​ inotropic support and triggers reflex bradycardia while simultaneously elevating LV afterload, phenylephrine routinely decreases stroke volume and cardiac index . It should be avoided in cardiogenic or septic cardiomyopathy.

Clinical Indications:

Hypotension driven by rapid supraventricular tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular response), where β 1 \beta_1 β 1 ​ -stimulating agents would provoke dangerous heart rate escalation.

Dynamic left ventricular outflow tract (LVOT) obstruction (hypertrophic obstructive cardiomyopathy [HOCM] or systolic anterior motion [SAM] of the mitral valve), where pure vasoconstriction increases afterload, expands the LV chamber, and widens the outflow orifice, relieving obstruction.

Neurogenic shock with isolated loss of vascular sympathetic tone.

Rapid temporary peripheral infusion bridge while central venous access is secured.

Dopamine: The Demise of the 'Renal Dose' and the SOAP II Trial

Dopamine is an immediate metabolic precursor to norepinephrine, exhibiting complex dose-dependent receptor affinities:

Dose-Dependent Receptor Targets:

Low Dose ( 0.5 – 3.0 μ g/kg/min 0.5\text{--}3.0\,\mu\text{g/kg/min} 0.5 – 3.0 μ g/kg/min ): Selectively stimulates post-junctional D 1 D_1 D 1 ​ dopaminergic receptors in renal, mesenteric, and coronary vasculature, promoting localized vasodilation and natriuresis.

Intermediate Dose ( 3.0 – 10.0 μ g/kg/min 3.0\text{--}10.0\,\mu\text{g/kg/min} 3.0 – 10.0 μ g/kg/min ): Stimulates cardiac β 1 \beta_1 β 1 ​ receptors (directly and by promoting endogenous norepinephrine release), increasing myocardial contractility and heart rate.

High Dose ( > 10.0 μ g/kg/min > 10.0\,\mu\text{g/kg/min} > 10.0 μ g/kg/min ): Overcomes dopaminergic and beta effects, with α 1 \alpha_1 α 1 ​ -adrenergic vasoconstriction dominating.

The 'Renal Dose' Dopamine Myth: Large-scale randomized clinical trials (such as the landmark ANZICS trial) demonstrated conclusively that low-dose dopamine does not protect against acute kidney injury, does not lower peak creatinine, does not decrease the need for renal replacement therapy, and does not improve ICU survival. Routine use of 'renal-dose' dopamine is obsolete and harmful.

The SOAP II Trial (De Backer et al., NEJM 2010): A multicenter randomized trial assigned 1,679 patients in shock (septic, cardiogenic, or hypovolemic) to receive either dopamine or norepinephrine as first-line vasopressor:

Overall 28-day mortality did not show a statistically significant difference (52.5% dopamine vs 48.5% norepinephrine, p = 0.10 p = 0.10 p = 0.10 ).

Dopamine provoked significantly more arrhythmic events (24.1% vs 12.4%, p < 0.001 p < 0.001 p < 0.001 ), primarily atrial fibrillation.

In the prespecified subgroup of 280 patients with cardiogenic shock , dopamine was associated with higher 28-day mortality in a Kaplan-Meier analysis ( p = 0.03 p = 0.03 p = 0.03 ), although the overall trial showed no mortality difference (52.5% vs. 48.5%, p = 0.10 p = 0.10 p = 0.10 ). Dopamine should not be used as first-line therapy in cardiogenic shock.

3. Inotropic & Inodilator Therapies: Dobutamine vs. Milrinone

In patients with primary myocardial pump failure or persistent tissue hypoperfusion despite adequate volume and MAP, inotropes are indicated to restore forward stroke volume. Comparison of Intracellular Inotropic Signaling:

• [ DOBUTAMINE ] ──> Stimulates β1 Receptors ──> Gs Protein ──> Adenylyl Cyclase ──> ↑ cAMP ──> PKA Activation
• │
• [ MILRINONE ] ──> Inhibits Phosphodiesterase-3 (PDE-3) ──> Blocks cAMP Breakdown ──────┘
• │
• ▼
• Phosphorylates L-Type Ca2+ Channels & SERCA/Phospholamban
• │
• ▼
• ↑ Peak Contractility (Inotropy) + ↑ Lusitropy (Relaxation)
• Dobutamine: Synthetic β 1 \beta_1 β 1 ​ -Selective Inotrope

Pharmacology: Synthetic catecholamine administered as a racemic mixture. The ( + ) (+) ( + ) enantiomer is a potent β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ agonist; the ( − ) (-) ( − ) enantiomer is an α 1 \alpha_1 α 1 ​ agonist. The net clinical effect is predominant β 1 \beta_1 β 1 ​ agonism with weak β 2 \beta_2 β 2 ​ vasodilation and minimal α 1 \alpha_1 α 1 ​ activity.

Hemodynamics: Marked enhancement of myocardial contractility, ejection fraction, and cardiac index. Mild systemic vasodilation decreases LV afterload, and augmented ventricular emptying lowers left ventricular end-diastolic pressure (LVEDP) and pulmonary capillary wedge pressure (PCWP). Net blood pressure effect depends on the balance between increased cardiac output and decreased SVR; in hypovolemic or severely vasoplegic patients, dobutamine triggers precipitous hypotension.

Pharmacokinetics: Ultra-short half-life ( t 1 / 2 ≈ 2 minutes t_{1/2} \approx 2\text{ minutes} t 1/2 ​ ≈ 2 minutes ); rapid onset and offset allow precise bedside titration ( 2.5 – 20.0 μ g/kg/min 2.5\text{--}20.0\,\mu\text{g/kg/min} 2.5 – 20.0 μ g/kg/min ).

Adverse Effects & Cautions: Tachycardia, ventricular ectopy, and increased myocardial oxygen demand ( M VO 2 M\text{VO}_2 M VO 2 ​ ). Prolonged infusions ( > 72 hours > 72\text{ hours} > 72 hours ) cause down-regulation and desensitization of β 1 \beta_1 β 1 ​ receptors (pharmacodynamic tolerance).

Milrinone: The Non-Adrenergic Inodilator

Mechanism of Action: Highly selective bipyridine inhibitor of phosphodiesterase type 3 (PDE-3). PDE-3 is the primary enzyme responsible for hydrolyzing cAMP to 5'-AMP in cardiac myocytes and vascular smooth muscle cells. By competitively blocking PDE-3, milrinone prevents cAMP degradation:

In cardiac myocytes: elevated cAMP enhances calcium influx and sarcoplasmic calcium recycling, producing potent inotropy and lusitropy.

In vascular smooth muscle: elevated cAMP accelerates calcium removal, producing robust relaxation of systemic arterioles and venules, as well as the pulmonary vascular bed.

Clinical Indications:

Right Ventricular (RV) Failure & Pulmonary Hypertension: Because milrinone produces profound pulmonary artery vasodilation, it markedly reduces pulmonary vascular resistance (PVR) and RV afterload while simultaneously augmenting RV contractility, making it the preferred inotrope for acute RV decompensation.

Chronic Beta-Blocker Therapy: Patients presenting with acute cardiogenic shock who take chronic, high-dose beta-blockers have occupied, internalized β 1 \beta_1 β 1 ​ receptors. Dobutamine is largely ineffective in this setting, whereas milrinone bypasses the beta-receptor entirely to elevate intracellular cAMP.

Critical Pharmacokinetics & Pitfalls:

Half-life is 2 to 3 hours in normal renal function, extending to 6 to 10+ hours in acute or chronic renal impairment.

Excretion is 80% to 90% renal as unchanged drug. In patients with acute kidney injury (AKI) or reduced GFR, milrinone accumulates rapidly, provoking intractable hypotension and ventricular arrhythmias. Infusion rates must be reduced by 50% to 75% in renal failure.

Omission of Bolus: Although the labeling includes an IV loading dose ( 50 μ g/kg 50\,\mu\text{g/kg} 50 μ g/kg over 10 minutes), most ICU clinicians omit the bolus in hypotensive or borderline patients because it can precipitate abrupt vasodilation and hypotension. Milrinone is usually started as a maintenance infusion ( 0.125 – 0.75 μ g/kg/min 0.125\text{--}0.75\,\mu\text{g/kg/min} 0.125 – 0.75 μ g/kg/min , reduced in renal impairment).

4. Comprehensive Vasoactive Agents Comparison Table

Agent Primary Receptor Affinities Hemodynamic Effect on SVR Effect on Cardiac Output Effect on Heart Rate Standard ICU Dose Range Primary Indications Key Adverse Effects & Clinical Pearls

Norepinephrine α 1 ≫ β 1 > β 2 \alpha_1 \gg \beta_1 > \beta_2 α 1 ​ ≫ β 1 ​ > β 2 ​ ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ ↔ / ↑ \leftrightarrow / \uparrow ↔ / ↑ ↔ / ↑ \leftrightarrow / \uparrow ↔ / ↑ (mild) 0.01 – 3.0 μ g/kg/min 0.01\text{--}3.0\,\mu\text{g/kg/min} 0.01 – 3.0 μ g/kg/min First-line in septic, distributive, and cardiogenic shock Low arrhythmogenicity; extravasation causes ischemic necrosis (phentolamine antidote).

Vasopressin V 1 V_1 V 1 ​ (vascular), V 2 V_2 V 2 ​ (renal) ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ ↔ / ↓ \leftrightarrow / \downarrow ↔ / ↓ ↔ / ↓ \leftrightarrow / \downarrow ↔ / ↓ (reflex) Fixed 0.03 units/min 0.03\text{ units/min} 0.03 units/min Catecholamine-sparing adjunct in septic shock; vasoplegic shock Do not titrate; doses > 0.04 U/min > 0.04\text{ U/min} > 0.04 U/min induce coronary, mesenteric and digital ischemia.

Epinephrine β 1 = β 2 > α 1 \beta_1 = \beta_2 > \alpha_1 β 1 ​ = β 2 ​ > α 1 ​ (low dose); α 1 > β 1 > β 2 \alpha_1 > \beta_1 > \beta_2 α 1 ​ > β 1 ​ > β 2 ​ (high dose) ↓ \downarrow ↓ (low dose); ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ (high dose) ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ 0.01 – 1.0 μ g/kg/min 0.01\text{--}1.0\,\mu\text{g/kg/min} 0.01 – 1.0 μ g/kg/min First-line in anaphylaxis and cardiac arrest; refractory septic shock Triggers transient aerobic Type B hyperlactatemia via skeletal β 2 \beta_2 β 2 ​ glycolysis; tachydysrhythmias.

Phenylephrine Pure α 1 \alpha_1 α 1 ​ ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ ↓ \downarrow ↓ ↓ ↓ \downarrow\downarrow ↓↓ (reflex) 0.1 – 5.0 μ g/kg/min 0.1\text{--}5.0\,\mu\text{g/kg/min} 0.1 – 5.0 μ g/kg/min Shock with rapid tachyarrhythmias; LVOT obstruction / HOCM Causes reflex bradycardia and decreases cardiac output; strictly avoid in primary pump failure.

Dopamine D 1 D_1 D 1 ​ (low dose); β 1 \beta_1 β 1 ​ (moderate dose); α 1 \alpha_1 α 1 ​ (high dose) ↔ \leftrightarrow ↔ (low/mod); ↑ ↑ \uparrow\uparrow ↑↑ (high) ↑ ↑ \uparrow\uparrow ↑↑ (mod/high) ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ 2.0 – 20.0 μ g/kg/min 2.0\text{--}20.0\,\mu\text{g/kg/min} 2.0 – 20.0 μ g/kg/min Alternative in bradycardia-induced shock; highly restricted SOAP II: higher tachyarrhythmias and increased mortality in cardiogenic shock; 'renal dose' is debunked.

Dobutamine β 1 ≫ β 2 > α 1 \beta_1 \gg \beta_2 > \alpha_1 β 1 ​ ≫ β 2 ​ > α 1 ​ ↓ \downarrow ↓ ↑ ↑ ↑ \uparrow\uparrow\uparrow ↑↑↑ ↑ ↑ \uparrow\uparrow ↑↑ 2.5 – 20.0 μ g/kg/min 2.5\text{--}20.0\,\mu\text{g/kg/min} 2.5 – 20.0 μ g/kg/min Cardiogenic shock with low output; acute decompensated heart failure Tachycardia; hypotension if unresuscitated; down-regulation of β 1 \beta_1 β 1 ​ receptors beyond 72 hr.

Milrinone PDE-3 Inhibitor (non-adrenergic) ↓ ↓ \downarrow\downarrow ↓↓ (SVR + PVR) ↑ ↑ \uparrow\uparrow ↑↑ ↔ / ↑ \leftrightarrow / \uparrow ↔ / ↑ 0.25 – 0.75 μ g/kg/min 0.25\text{--}0.75\,\mu\text{g/kg/min} 0.25 – 0.75 μ g/kg/min RV failure, pulmonary hypertension, cardiogenic shock on beta-blockers Long t 1 / 2 t_{1/2} t 1/2 ​ (2-3 hr); renal elimination (accumulates in AKI); omit loading bolus to avoid hypotension.

• 5. Clinical Titration Protocols & Safety Management
• Arterial Line & Central Line Monitoring

Continuous Blood Pressure Monitoring: Whenever escalating vasopressor infusions are required, an indwelling radial, femoral, or axillary arterial catheter is mandatory. Non-invasive cuff blood pressure cuffs substantially underestimate true central arterial pressure in states of profound peripheral vasoconstriction.

Peripheral Extravasation & Antidote: Peripheral vasopressor infusions through dedicated large-bore antecubital veins are acceptable as a temporary bridge ( < 24 – 48 hours < 24\text{--}48\text{ hours} < 24 – 48 hours ), but central venous access should be obtained expediently. In the event of peripheral extravasation of an α 1 \alpha_1 α 1 ​ agonist, immediately infiltrate the area with phentolamine (5 to 10 mg diluted in 10 to 15 mL normal saline) via fine subcutaneous needles to block local alpha receptors and prevent ischemic skin sloughing.

Warning

Never administer pure alpha-1 agonists (phenylephrine) or high-dose vasopressin in unmonitored cardiogenic shock with an unvented, failing left ventricle. The sudden escalation in afterload without inotropic augmentation precipitates acute pulmonary edema and left ventricular dilation.